Want to see SRRK full AI Analyst Report?
SRRK Stock Chart & Stats
$47.67
-$1.81(-3.66%)
At close: 4:00 PM EDT
$47.67
-$1.81(-3.66%)
Day’s Range― - ―
52-Week Range$27.07 - $58.49
Previous Close$47.67
Volume838.71K
Average Volume (3M)1.53M
Market Cap
$5.71B
Enterprise Value$5.98K
Total Cash (Recent Filing)$479.94M
Total Debt (Recent Filing)$205.67M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 06, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.45
Shares Outstanding119,828,340
10 Day Avg. Volume1,038,028
30 Day Avg. Volume1,529,778
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$59.56Price Target Upside24.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$6.27M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressBLA acceptance with a set PDUFA date converts regulatory uncertainty into a defined approval timeline. That structural milestone, if successful, enables transition from R&D to commercial operations, potential product revenue, and reduced long-term financing dependency, materially altering the company’s operating profile.
Dual Manufacturing/Supply PathHaving two independent fill‑finish sites provides durable operational resilience versus single-site exposure. This reduces launch and supply-chain tail risk, mitigates the impact of Catalent's pending FDA classification, and strengthens the company’s ability to meet demand and negotiate payer/provider contracts upon approval.
Cash & Financing OptionalityA sizable cash position plus access to debt, ATM proceeds, an approval‑contingent $150M draw and a planned PRV monetization create meaningful runway and financing flexibility. Structurally, this reduces immediate dilution risk and supports ongoing R&D and commercial investments through regulatory and early launch phases.
Bears Say
High Ongoing Cash BurnPersistent ~300M annual cash outflows are a structural vulnerability: absent timely product revenue or milestone monetization, the company must continually access capital markets or debt, increasing dilution and financial risk. Sustained burn constrains long-term investment flexibility and heightens execution pressure.
Rising LeverageDebt growth and a higher debt/equity ratio (~0.75x TTM) reduce financial flexibility and raise servicing and covenant exposure. For a pre‑revenue biotech, increasing leverage amplifies funding risk during commercialization, limits strategic optionality, and can increase cost of capital over the medium term.
No Product Revenue; Heavy Pre‑Commercial SpendZero product revenue combined with substantial pre‑commercial operating costs means profitability hinges on successful approval, launch execution, label scope and payer uptake. This structural gap makes long‑term sustainability conditional on commercialization converting investment into durable sales.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding’s price range in the past 12 months?
Scholar Rock Holding lowest stock price was $27.07 and its highest was $58.49 in the past 12 months.
What is Scholar Rock Holding’s market cap?
Scholar Rock Holding’s market cap is $5.71B.
When is Scholar Rock Holding’s upcoming earnings report date?
Scholar Rock Holding’s upcoming earnings report date is Aug 06, 2026 which is in 9 days.
How were Scholar Rock Holding’s earnings last quarter?
Scholar Rock Holding released its earnings results on May 07, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.8 by -$0.03.
Is Scholar Rock Holding overvalued?
According to Wall Street analysts Scholar Rock Holding’s price is currently Undervalued.
Does Scholar Rock Holding pay dividends?
Scholar Rock Holding does not currently pay dividends.
What is Scholar Rock Holding’s EPS estimate?
Scholar Rock Holding’s EPS estimate is -0.84.
How many shares outstanding does Scholar Rock Holding have?
Scholar Rock Holding has 119,828,340 shares outstanding.
What happened to Scholar Rock Holding’s price movement after its last earnings report?
Scholar Rock Holding reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.8. Following the earnings report the stock price went down -1.401%.
Which hedge fund is a major shareholder of Scholar Rock Holding?
Currently, no hedge funds are holding shares in SRRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.56 (24.93% Upside)
$59.56 (24.93% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 183.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 11.2%
Last 30 Days ▼ 11.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.33%
Trailing 12-Months
Company Description
Scholar Rock Holding
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
SRRK Company Deck
SRRK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: FDA accepted the BLA with a clear PDUFA date (Sept 30, 2026), the company has created dual manufacturing paths (second facility supplying product in early Q3), European review appears on track for midyear, and the balance sheet and commercial infrastructure were strengthened during the quarter. Key risks remain focused on regulatory classification of the Catalent Indiana site, continued manufacturing/regulatory uncertainty until that classification, high pre-commercial operating spend, and the need to monetize financing levers (debt/ATM/PRV). On balance, the material positive developments (BLA acceptance, dual fill-finish strategy, clear supply path, strong cash position, pipeline progression and commercial readiness) outweigh the remaining lowlights and uncertainties.View all SRRK earnings summariesSRRK Stock 12 Month Forecast
Average Price Target
$59.56
▲(24.93% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
20.63% Insiders
30.07% Mutual Funds
0.63% Other Institutional Investors
36.31% Public Companies and
Individual Investors